SG11202006063RA - Pic1 inhibition of myeloperoxidase oxidative activity in an animal model - Google Patents
Pic1 inhibition of myeloperoxidase oxidative activity in an animal modelInfo
- Publication number
- SG11202006063RA SG11202006063RA SG11202006063RA SG11202006063RA SG11202006063RA SG 11202006063R A SG11202006063R A SG 11202006063RA SG 11202006063R A SG11202006063R A SG 11202006063RA SG 11202006063R A SG11202006063R A SG 11202006063RA SG 11202006063R A SG11202006063R A SG 11202006063RA
- Authority
- SG
- Singapore
- Prior art keywords
- pic1
- myeloperoxidase
- inhibition
- animal model
- oxidative activity
- Prior art date
Links
- 101100243951 Caenorhabditis elegans pie-1 gene Proteins 0.000 title 1
- 102000003896 Myeloperoxidases Human genes 0.000 title 1
- 108090000235 Myeloperoxidases Proteins 0.000 title 1
- 238000010171 animal model Methods 0.000 title 1
- 230000005764 inhibitory process Effects 0.000 title 1
- 230000001590 oxidative effect Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/005—Enzyme inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/00022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/00033—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Transplantation (AREA)
- Virology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Wood Science & Technology (AREA)
- Peptides Or Proteins (AREA)
- General Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862615183P | 2018-01-09 | 2018-01-09 | |
| US201862681458P | 2018-06-06 | 2018-06-06 | |
| US201862746649P | 2018-10-17 | 2018-10-17 | |
| PCT/US2019/012659 WO2019139886A1 (en) | 2018-01-09 | 2019-01-08 | Pic1 inhibition of myeloperoxidase oxidative activity in an animal model |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202006063RA true SG11202006063RA (en) | 2020-07-29 |
Family
ID=67140101
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202006063RA SG11202006063RA (en) | 2018-01-09 | 2019-01-08 | Pic1 inhibition of myeloperoxidase oxidative activity in an animal model |
Country Status (11)
| Country | Link |
|---|---|
| US (4) | US11135272B2 (es) |
| EP (1) | EP3740074A4 (es) |
| JP (2) | JP7031011B2 (es) |
| KR (2) | KR102420552B1 (es) |
| CN (1) | CN112512548A (es) |
| AU (2) | AU2019207508B2 (es) |
| CA (1) | CA3086407A1 (es) |
| IL (2) | IL287308B2 (es) |
| MX (1) | MX2020007098A (es) |
| SG (1) | SG11202006063RA (es) |
| WO (1) | WO2019139886A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10947279B2 (en) | 2015-06-26 | 2021-03-16 | Realta Holdings, Llc | Synthetic peptide compounds and methods of use |
| US20240010681A1 (en) * | 2020-09-30 | 2024-01-11 | Realta Life Sciences, Inc. | Peptides and methods of use |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5625049A (en) | 1993-05-12 | 1997-04-29 | Us Health | Nucleic acids encoding human astrovirus serotype 2 |
| US6126939A (en) | 1996-09-03 | 2000-10-03 | Yeda Research And Development Co. Ltd. | Anti-inflammatory dipeptide and pharmaceutical composition thereof |
| AU3066699A (en) | 1998-03-03 | 1999-09-20 | Johns Hopkins University, The | Smallpox inhibitor of complement enzymes (spice) protein and methods of inhibiting complement activation |
| WO2000043027A1 (en) | 1999-01-19 | 2000-07-27 | University Of Louisville Research Foundation, Inc. | Application of a viral complement inhibitory protein in the treatment and diagnosis of alzheimer's disease |
| US6696562B1 (en) | 2000-07-10 | 2004-02-24 | The United States Of America As Represented By The Secretary Of Agriculture | Avian astrovirus |
| KR101132287B1 (ko) | 2003-09-05 | 2012-04-05 | 도레이 도넨 기노마쿠 고도가이샤 | 열가소성 수지 미다공막의 제조 방법 |
| US20070116672A1 (en) | 2003-09-05 | 2007-05-24 | Kotwal Girish J | Treatment of rheumatic diseases |
| WO2005023195A2 (en) | 2003-09-05 | 2005-03-17 | University Of Louisville Research Foundation, Inc. | Treatment of spinal cord injury |
| US8501705B2 (en) | 2003-09-11 | 2013-08-06 | The Board Of Regents Of The University Of Texas System | Methods and materials for treating autoimmune and/or complement mediated diseases and conditions |
| US7381524B2 (en) | 2003-10-10 | 2008-06-03 | Wisconsin Alumni Research Foundation | Method to detect antibodies specific for type-2 turkey astrovirus |
| US8840893B2 (en) | 2004-06-10 | 2014-09-23 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
| US8241843B2 (en) | 2006-06-15 | 2012-08-14 | Eastern Virginia Medical School | Methods for regulating complement cascade proteins using astrovirus coat protein and derivatives thereof |
| US7956161B2 (en) | 2007-04-11 | 2011-06-07 | Pestka Biomedical Laboratories, Inc. | Interferons of rhesus and cynomolgus origin and uses thereof |
| US10172950B2 (en) | 2009-06-09 | 2019-01-08 | Prolong Pharmaceuticals, LLC | Hemoglobin compositions |
| WO2011131772A1 (en) | 2010-04-22 | 2011-10-27 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Means and methods for identifying an increased risk of systemic lupus erythematosus (sle) patients for developing renal manifestations |
| US10005818B2 (en) * | 2010-07-21 | 2018-06-26 | Realta Holdings, Llc | Derivative peptide compounds and methods of use |
| ES2688589T3 (es) | 2010-07-21 | 2018-11-05 | Eastern Virginia Medical School | Compuestos peptídicos para regular el sistema del complemento |
| WO2013138694A1 (en) | 2012-03-16 | 2013-09-19 | Enzon Pharmaceuticals, Inc. | Polymeric conjugates of c-1 inhibitors |
| EP3313865B1 (en) | 2015-06-26 | 2021-04-07 | ReAlta Holdings, LLC | Synthetic peptide compounds and methods of use |
-
2019
- 2019-01-08 CA CA3086407A patent/CA3086407A1/en active Pending
- 2019-01-08 IL IL287308A patent/IL287308B2/en unknown
- 2019-01-08 SG SG11202006063RA patent/SG11202006063RA/en unknown
- 2019-01-08 US US16/242,550 patent/US11135272B2/en active Active
- 2019-01-08 JP JP2020557135A patent/JP7031011B2/ja active Active
- 2019-01-08 AU AU2019207508A patent/AU2019207508B2/en active Active
- 2019-01-08 KR KR1020207022678A patent/KR102420552B1/ko active IP Right Grant
- 2019-01-08 WO PCT/US2019/012659 patent/WO2019139886A1/en active Application Filing
- 2019-01-08 CN CN201980007577.6A patent/CN112512548A/zh active Pending
- 2019-01-08 KR KR1020227023661A patent/KR20220104268A/ko not_active Application Discontinuation
- 2019-01-08 MX MX2020007098A patent/MX2020007098A/es unknown
- 2019-01-08 EP EP19738307.8A patent/EP3740074A4/en active Pending
-
2020
- 2020-04-03 US US16/839,464 patent/US11020460B2/en active Active
- 2020-07-06 IL IL275867A patent/IL275867B/en unknown
-
2021
- 2021-04-30 US US17/245,213 patent/US11712462B2/en active Active
-
2022
- 2022-02-22 JP JP2022025426A patent/JP7341268B2/ja active Active
-
2023
- 2023-06-09 US US18/332,026 patent/US20230321201A1/en active Pending
-
2024
- 2024-07-31 AU AU2024205230A patent/AU2024205230A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2019207508B2 (en) | 2024-05-02 |
| US20210252113A1 (en) | 2021-08-19 |
| US20190209660A1 (en) | 2019-07-11 |
| KR20200138168A (ko) | 2020-12-09 |
| US11712462B2 (en) | 2023-08-01 |
| US20230321201A1 (en) | 2023-10-12 |
| IL275867A (en) | 2020-08-31 |
| JP2021509916A (ja) | 2021-04-08 |
| IL287308B2 (en) | 2024-03-01 |
| US11020460B2 (en) | 2021-06-01 |
| JP2022068323A (ja) | 2022-05-09 |
| IL275867B (en) | 2022-01-01 |
| US11135272B2 (en) | 2021-10-05 |
| CN112512548A (zh) | 2021-03-16 |
| KR102420552B1 (ko) | 2022-07-13 |
| JP7031011B2 (ja) | 2022-03-07 |
| AU2019207508A1 (en) | 2020-07-09 |
| US20200230212A1 (en) | 2020-07-23 |
| MX2020007098A (es) | 2020-11-11 |
| IL287308B1 (en) | 2023-11-01 |
| CA3086407A1 (en) | 2019-07-18 |
| EP3740074A1 (en) | 2020-11-25 |
| IL287308A (en) | 2021-12-01 |
| WO2019139886A1 (en) | 2019-07-18 |
| EP3740074A4 (en) | 2021-10-13 |
| AU2024205230A1 (en) | 2024-09-05 |
| KR20220104268A (ko) | 2022-07-26 |
| JP7341268B2 (ja) | 2023-09-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL288264A (en) | Genetically engineered non-human animals that express human erythropoietin | |
| IL287308A (en) | pic1 inhibition of myeloperoxidase oxidative activity in an animal model | |
| MX2019005251A (es) | Animales no humanos geneticamente modificados y metodos de uso de los mismos. | |
| MX2014015679A (es) | Roedores con il-7 humanizada. | |
| ZA201904522B (en) | Heterocyclic inhibitors of mct4 | |
| CY1123216T1 (el) | Αναστολεις της gls1 για την αντιμετωπιση νοσων | |
| GB201911615D0 (en) | Improvements relating to animal beds | |
| EP3751993C0 (en) | CATTLE BARN WITH AIR PURIFIER | |
| CA187828S (en) | Rib pet treat | |
| CA187950S (en) | Pet treat | |
| PL3310178T3 (pl) | Sposób i układ ogłuszania i/lub uśmiercania zwierząt | |
| PL3369298T3 (pl) | Sposób redukcji zapachu i przetwarzania ekskrementów zwierzęcych | |
| GB201815820D0 (en) | Off-target activity inhibitors for guided endonucleases | |
| DE112019003168A5 (de) | Tierpflege - und/oder Reinigungsvorrichtung | |
| GB201902996D0 (en) | Animal footbath appparatus | |
| GB201705386D0 (en) | Device for use in the humane slaughter of animals | |
| CA200418S (en) | Cat scratcher | |
| AU201817513S (en) | Pet animal activity mat | |
| IL264980A (en) | Animal treatment complex | |
| AU201817515S (en) | Pet activity mat | |
| PL2999329T3 (pl) | Lizofosfolipidy i alkilolizofosfolipidy przeciw chorobom czerwia pszczelego | |
| GB201816612D0 (en) | Animal & bird deterrent using electrical energy | |
| SG10201907983UA (en) | Animal Deterrent | |
| PL3799719T3 (pl) | Obróbka tuszy zwierzęcej po uboju | |
| GB201901798D0 (en) | Human activity system |